A Boulder biotech working on genome engineering said it's raised $23 million in a Series B round of funding. Muse bio said the funding round was led by Venrock and included investments from Foresite Capital and Paladin Capital, and original investors NanoDimension and Spruce/MLS. "Muse bio's technology ...
Read MoreThe treatment or cure of HIV infection by cell and gene therapy has been a goal for decades. Recent advances in both gene editing and chimeric antigen receptor (CAR) technology have created new therapeutic possibilities for a variety of diseases. Broadly neutralizing monoclonal antibodies (bNAbs) with specificity for the HIV envelope glycoprotein provide a promising means of targeting HIV-infected cells. Here we show that primary human...
Read More
Abstract Background RNAi (RNA interference) is a technology for silencing of target genes via sequence-specific manner. RNAi technology has been used for development of anti-pathogenic crops. In 2007, development of transgenic plants resistant to insect herbivore using RNAi technology was first reported, leading to a burst of efforts aimed at exploitation of RNAi mechanism and control strategy against variety of insect species based on this technique. Mythimna...
Read More
In an effort to improve the survival rate of cancer patients, the Mhlanga Lab has teamed up with the CSIR to understand the genetic mutations that characterise some cancers, and use this to identify chemotherapeutic agents that will provide the best clinical outcomes. Chemotherapeutic drugs are the heavy artillery in the fight against cancer, but they are still highly toxic to all rapidly-dividing cells in the body, leading...
Read More